$75.70 Million in Sales Expected for Neurocrine Biosciences, Inc. (NBIX) This Quarter
Wall Street analysts expect Neurocrine Biosciences, Inc. (NASDAQ:NBIX) to post $75.70 million in sales for the current quarter, according to Zacks Investment Research. Eight analysts have made estimates for Neurocrine Biosciences’ earnings, with the highest sales estimate coming in at $84.60 million and the lowest estimate coming in at $57.00 million. The firm is scheduled to announce its next earnings report on Tuesday, February 13th.
On average, analysts expect that Neurocrine Biosciences will report full year sales of $75.70 million for the current year, with estimates ranging from $65.10 million to $151.67 million. For the next year, analysts expect that the business will report sales of $313.38 million per share, with estimates ranging from $196.30 million to $511.00 million. Zacks’ sales averages are a mean average based on a survey of research analysts that cover Neurocrine Biosciences.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to analyst estimates of $29.38 million. During the same period in the previous year, the business earned ($0.43) EPS.
Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at $73.60 on Friday. Neurocrine Biosciences has a one year low of $37.35 and a one year high of $75.98. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05.
In other news, insider Christopher Flint Obrien sold 52,817 shares of the stock in a transaction that occurred on Tuesday, September 5th. The stock was sold at an average price of $57.50, for a total transaction of $3,036,977.50. Following the transaction, the insider now owns 101,790 shares in the company, valued at approximately $5,852,925. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, insider Kyle Gano sold 24,818 shares of the firm’s stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $71.05, for a total value of $1,763,318.90. Following the completion of the transaction, the insider now owns 84,596 shares in the company, valued at approximately $6,010,545.80. The disclosure for this sale can be found here. Insiders have sold a total of 150,710 shares of company stock worth $9,758,593 in the last quarter. Insiders own 4.80% of the company’s stock.
A number of hedge funds have recently made changes to their positions in NBIX. Janus Henderson Group PLC purchased a new position in Neurocrine Biosciences in the 2nd quarter valued at $246,888,000. TimesSquare Capital Management LLC lifted its holdings in Neurocrine Biosciences by 299.4% in the 2nd quarter. TimesSquare Capital Management LLC now owns 2,315,373 shares of the company’s stock valued at $106,507,000 after purchasing an additional 1,735,700 shares in the last quarter. HealthCor Management L.P. lifted its holdings in Neurocrine Biosciences by 108.2% in the 2nd quarter. HealthCor Management L.P. now owns 2,550,178 shares of the company’s stock valued at $117,308,000 after purchasing an additional 1,325,178 shares in the last quarter. Perceptive Advisors LLC lifted its holdings in Neurocrine Biosciences by 33.9% in the 3rd quarter. Perceptive Advisors LLC now owns 4,791,589 shares of the company’s stock valued at $293,629,000 after purchasing an additional 1,214,000 shares in the last quarter. Finally, FMR LLC lifted its holdings in Neurocrine Biosciences by 9.8% in the 2nd quarter. FMR LLC now owns 13,211,023 shares of the company’s stock valued at $607,707,000 after purchasing an additional 1,180,874 shares in the last quarter.
COPYRIGHT VIOLATION NOTICE: This piece was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/12/02/75-70-million-in-sales-expected-for-neurocrine-biosciences-inc-nbix-this-quarter.html.
About Neurocrine Biosciences
Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Neurocrine Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.